News >

Pivotal Trials With CDK4/6, PI3K Inhibitors Propel Progress in HR+ Breast Cancer

Ellie Leick
Published: Wednesday, Aug 14, 2019

Leticia Varella, MD

Leticia Varella, MD

Findings of the MONALEESA-7 and SOLAR-1 studies demonstrated intriguing findings for patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer, and those with PIK3CA-mutated breast cancer, respectively, explained Leticia Varella, MD.

The phase III MONALEESA-7 trial examined ribociclib (Kisqali) and endocrine therapy in previously untreated pre- and perimenopausal women. Updated data showed that, at a median follow-up of 42 months, 70.2% of patients who received the combination were alive versus 46% of patients who received endocrine therapy alone, which translated to a 29% reduction in the risk of death (HR, 0.71; 95% CI, 0.54-0.95; P = .0097).1

Additionally, results of the SOLAR-1 trial showed that the addition of the PI3K inhibitor alpelisib (Piqray) to fulvestrant (Faslodex) improved progression-free survival (PFS) compared with fulvestrant alone for postmenopausal patients with HR-positive, HER2-negative breast cancer and harbor PIK3CA mutations. The median PFS was 11.0 months versus 5.7 months with fulvestrant alone at a median follow-up of 20 months, which led to a 35% reduction in the risk of disease progression or death (HR, 0.65; 95% CI, 0.50-0.85; P = .00065).2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication